RecruitingPhase 1NCT07333261

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma

Sponsor

Susan Bal

Enrollment

25 participants

Start Date

Feb 9, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug combination called BMS-986453 in people who have been newly diagnosed with multiple myeloma (a type of blood cancer) and are not able to undergo a stem cell transplant. The goal is to find a safer, effective treatment option for this group. **You may be eligible if...** - You are over 18 years old - You have been newly diagnosed with multiple myeloma within the last 12 months - You are not eligible for or do not wish to have a stem cell transplant - Your overall health and organ function meet study requirements (ECOG 0–1) **You may NOT be eligible if...** - Your myeloma has spread to the brain or spinal cord - You have a related but different blood disorder (e.g., plasma cell leukemia, POEMS, or amyloidosis) - You have had another cancer previously - You have an uncontrolled infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.